Sartorius Stedim Biotech S.A.
MarketLine (a Datamonitor Company)
26 Nov 2013
Available for Immediate Download
Sartorius Stedim Biotech S.A. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Sartorius Stedim Biotech S.A. required for business and competitor intelligence needs - Intelligence on Sartorius Stedim Biotech S.A.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Sartorius Stedim Biotech S.A., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Sartorius Stedim Biotech, formerly Stedim Biosystems, is a provider of equipments and services for the development, quality assurance and production processes of the biopharmaceutical industry. The company operates in Europe, the Americas and Asia Pacific. It is headquartered in Aubagne, France, and employs around 2,581 people. The company recorded revenues of E432.9 million (approximately $574.9 million) in the fiscal year ended December 2010, an increase of 7.9% over 2009. The company's operating profit was E59.9 million (approximately $79.5 million) in fiscal 2010, an increase of 23.2% over 2009. Its net profit was E38.5 million (approximately $51.1 million) in fiscal 2010, an increase of 32.4% over 2009. Reasons to Purchase: - Gain understanding of Sartorius Stedim Biotech S.A. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Sartorius Stedim Biotech S.A. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Sartorius Stedim Biotech S.A. your competitors' business structure, strategy and prospects